REGADENOSON MYOCARDIAL PERFUSION SCINTIGRAPHY: A SINGLE CENTRE EXPERIENCE.

Area of Science:

• Cardiology
• Nuclear Medicine
• Pharmacology

Background:

• Regadenoson is a selective A2A adenosine receptor agonist.
• It is utilized for stress myocardial perfusion scintigraphy.

Purpose of the Study:

• To evaluate the safety and initial experience of using Regadenoson as a myocardial perfusion stress agent.
• To assess adverse events associated with Regadenoson in scintigraphy.

Main Methods:

• Adult patients undergoing stress myocardial perfusion scintigraphy were included after ethical approval.
• Exclusion criteria included specific cardiac conditions like AV block and recent myocardial infarction.
• Demographic data, comorbidities, vitals, and adverse events were systematically recorded.

Main Results:

• Sixty-three patients (63.5% male, mean age 56.81 years) were analyzed.
• The most common comorbidity was hyperlipidemia (47.6%).
• Transient decreases in blood pressure were observed, normalizing within 60 minutes. No serious adverse effects were reported, with transient ST depression in 8.3% and common side effects including dyspnea (23.8%) and headache (21.4%).

Conclusions:

• Regadenoson is associated with transient hemodynamic alterations.
• Reported adverse effects were non-serious and transient.
• The study supports Regadenoson's safety for stress myocardial perfusion scintigraphy.